Formulary Watch |

All News - Page 26

FDA Approves First Pediatric Indication for Blockbuster Eylea
FDA Approves First Pediatric Indication for Blockbuster Eylea
FDA Approves First Pediatric Indication for Blockbuster Eylea
February 9, 2023
Eylea now also treats retinopathy of prematurity, a leading cause of childhood blindness worldwide.
Study: Lower Rebates, and Lower Prices, Lead to Lower Patient Costs
Study: Lower Rebates, and Lower Prices, Lead to Lower Patient Costs
Study: Lower Rebates, and Lower Prices, Lead to Lower Patient Costs
February 8, 2023
In a real-world example, investigators found that lowered pricing of prescription drugs results in lower patient out-of-pocket costs, particularly for those patients with coinsurance.
CVS Pharmacy Services Revenue up 10.6% for 2022
CVS Pharmacy Services Revenue up 10.6% for 2022
CVS Pharmacy Services Revenue up 10.6% for 2022
February 8, 2023
In 2023, CVS executives expect revenue in pharmacy services to grow by 1% to 2% driven by generic and biosimilar launches.
States, not Federal Government, Are Moving to Tighten Regulation of PBMs
States, not Federal Government, Are Moving to Tighten Regulation of PBMs
States, not Federal Government, Are Moving to Tighten Regulation of PBMs
February 7, 2023
In 2022, 12 states have enacted 19 pieces of legislation that put a variety of restrictions and requirements on pharmacy benefit managers (PBMs).
FDA Sets PDUFA Date for Dry Eye Disease Drug
FDA Sets PDUFA Date for Dry Eye Disease Drug
FDA Sets PDUFA Date for Dry Eye Disease Drug
February 7, 2023
If approved, reproxalap would be the first inhibitor of RASP to treat patients with dry eye disease. The FDA PDUFA date is Nov. 23, 2023.
FDA Okays Pediatric Indication for Takeda’s Takhzyro
FDA Okays Pediatric Indication for Takeda’s Takhzyro
FDA Okays Pediatric Indication for Takeda’s Takhzyro
February 6, 2023
Takhzyro is the first therapy to prevent attacks of hereditary angioedema (HAE) in children ages 2 to under 6.
FDA Accepts NDA for Zuranolone for Depression
FDA Accepts NDA for Zuranolone for Depression
FDA Accepts NDA for Zuranolone for Depression
February 6, 2023
Zuranolone is a rapid-acting neuroactive steroid that can take effect in 14 days to treat patients with major depressive disorder and postpartum depression. The FDA has assigned a PDUFA action date of Aug. 5, 2023.
Credit: CDC/ National Institute of Allergy and Infectious Diseases (NIAID)
FDA Warns Companies Claiming to Treat Monkeypox
FDA Warns Companies Claiming to Treat Monkeypox
February 4, 2023
The products may be ineffective, unsafe and could prevent a person from seeking an appropriate diagnosis.
FDA Approves Trodelvy for HR+/HER2- Breast Cancer
FDA Approves Trodelvy for HR+/HER2- Breast Cancer
FDA Approves Trodelvy for HR+/HER2- Breast Cancer
February 3, 2023
Trodelvy has been recommended as a preferred treatment for metastatic HR+/HER2- breast cancer by the National Comprehensive Cancer Network.
FDA Approves Tezspire in Pre-Filled Pen
FDA Approves Tezspire in Pre-Filled Pen
FDA Approves Tezspire in Pre-Filled Pen
February 3, 2023
Tezspire is a biologic that specifically targets the inflammation associated with asthma.
Cigna’s Evernorth Division Contributed $140 million in 2022 Revenue
Cigna’s Evernorth Division Contributed $140 million in 2022 Revenue
Cigna’s Evernorth Division Contributed $140 million in 2022 Revenue
February 3, 2023
Evernorth, Cigna’s pharmacy and benefits solutions division, contributed more than 75% of the company’s revenue last year.
Will the Biosimilar Amjevita Lower Costs?
Will the Biosimilar Amjevita Lower Costs?
Will the Biosimilar Amjevita Lower Costs?
February 2, 2023
The real impact may not likely be seen until after July when additional biosimilars referencing Humira are launched.
FDA Approves Novel Therapy for CKD-Related Anemia
FDA Approves Novel Therapy for CKD-Related Anemia
FDA Approves Novel Therapy for CKD-Related Anemia
February 2, 2023
Daprodustat, now with the brand name of Jesduvroq, is a new oral therapy but it carries a boxed warning about the risk of cardiovascular events.
Subpotency Leads to Recall of 27 Lots of Tirosint-SOL
Subpotency Leads to Recall of 27 Lots of Tirosint-SOL
Subpotency Leads to Recall of 27 Lots of Tirosint-SOL
February 2, 2023
IBSA Pharma is recalling the hypothyroid medication because analyses showed lowered levels of levothyroxine in some lots.
Daiichi Sankyo Makes Available New Dosing Regimen for Turalio
Daiichi Sankyo Makes Available New Dosing Regimen for Turalio
Daiichi Sankyo Makes Available New Dosing Regimen for Turalio
February 1, 2023
Dosing has been lowered to reduce the risk of liver damage in patients taking Turalio, which is approved to treat patients with a rare tumor that affects the joints.
Hospital Drug Spending to Increase through July 2024
Hospital Drug Spending to Increase through July 2024
Hospital Drug Spending to Increase through July 2024
January 31, 2023
Vizient is forecasting a 3.78% rise in pharmacy prices in hospitals and non-acute care facilities, reflecting increases in both prices and utilization.
First Humira Biosimilar is Now Available
First Humira Biosimilar is Now Available
First Humira Biosimilar is Now Available
January 31, 2023
Some PBMs will offer Amgen’s Amjevita biosimilar as a preferred product alongside Humira, but CVS Caremark said Humira will remain preferred and Amjevita will be placed on a non-preferred brand tier.
Mark Cuban’s Pharmacy Teams up With Cancer Health App
Mark Cuban’s Pharmacy Teams up With Cancer Health App
Mark Cuban’s Pharmacy Teams up With Cancer Health App
January 30, 2023
The collaboration between Cost Plus Drugs and OncoPower provides access to generic medications for patients with cancer integrated with OncoPower’s Pill Reminder tool.
Senators Reintroduce PBM Legislation
Senators Reintroduce PBM Legislation
Senators Reintroduce PBM Legislation
January 30, 2023
The proposed legislation, sponsored by Sens. Chuck Grassley and Maria Cantwell, aims to increase transparency of PBM business practices.
FDA Approves Orserdu to Treat Metastatic Breast Cancer
FDA Approves Orserdu to Treat Metastatic Breast Cancer
FDA Approves Orserdu to Treat Metastatic Breast Cancer
January 30, 2023
Elacestrant, now with the brand name Orserdu, is an oral selective estrogen receptor degrader (SERD), which works by blocking the effects of estrogen on hormone receptor-positive breast cancer cells.
FDA Approves Lilly’s BTK Inhibitor for Rare Blood Cancer
FDA Approves Lilly’s BTK Inhibitor for Rare Blood Cancer
FDA Approves Lilly’s BTK Inhibitor for Rare Blood Cancer
January 27, 2023
Jaypirca is the first BTK inhibitor specifically approved for patients with mantle cell lymphoma previously treated with a covalent BTK inhibitor. It has a wholesale acquisition cost of $21,000 per 30 days of therapy.
FDA Approves Keytruda for Lung Cancer After Surgery
FDA Approves Keytruda for Lung Cancer After Surgery
FDA Approves Keytruda for Lung Cancer After Surgery
January 27, 2023
This approval marks the fifth indication for Keytruda-based regimens in non-small cell lung cancer and the 34th indication in the United States.
IQVIA: Accumulator and Maximizer Programs are Growing
IQVIA: Accumulator and Maximizer Programs are Growing
IQVIA: Accumulator and Maximizer Programs are Growing
January 27, 2023
Programs that do not count pharmaceutical company coupons and copay assistance toward deductibles have grown over the last five years, but states are stepping in to limit these programs.
FDA Removes Evusheld’s EUA for COVID-19
FDA Removes Evusheld’s EUA for COVID-19
FDA Removes Evusheld’s EUA for COVID-19
January 27, 2023
AstraZeneca is developing a next-generation long-acting antibody for pre-exposure prophylaxis of COVID-19, which it plans to make available in the second half of 2023.
Flipt, Evio Partner on Pharmacy Benefit Solution for Employers
Flipt, Evio Partner on Pharmacy Benefit Solution for Employers
Flipt, Evio Partner on Pharmacy Benefit Solution for Employers
January 26, 2023
Evio is launching a new pharmacy solution that leverages Flipt’s proprietary, cloud-based benefit administration and patient engagement platforms.
Analysis: Payers Restrict Medications for Autoimmune Diseases
Analysis: Payers Restrict Medications for Autoimmune Diseases
Analysis: Payers Restrict Medications for Autoimmune Diseases
January 26, 2023
Three out of four health plans scored a “C” or an “F” because of utilization management restrictions they place on medication for autoimmune conditions.
Payers and Specialty Drugs
Payers and Specialty Drugs
Payers and Specialty Drugs
January 26, 2023
In this video, Dea Belazi, president and chief executive officer of AscellaHealth, discusses how payers will approach specialty drugs.
Study: Heart Failure Patients Could Save with Inflation Reduction Act
Study: Heart Failure Patients Could Save with Inflation Reduction Act
Study: Heart Failure Patients Could Save with Inflation Reduction Act
January 25, 2023
The Inflation Reduction Act’s cap on annual out-of-pocket spending and changes to coverage gaps could save Medicare patients more than $1,000 on heart failure medications.
AAM Report: PBMs, Health Plans Delay Adoption of Generics
AAM Report: PBMs, Health Plans Delay Adoption of Generics
AAM Report: PBMs, Health Plans Delay Adoption of Generics
January 25, 2023
The Association for Accessible Medicines’ report indicates plans, especially those in Medicare, are slower to prefer first generics.
Amazon Launches Subscription-Based Med Service
Amazon Launches Subscription-Based Med Service
Amazon Launches Subscription-Based Med Service
January 24, 2023
Amazon Prime members can access generic medications from an eligible list with free delivery for an additional $5 a month.
<1
...
222324252627282930
...
226>
© 2024 MJH Life Sciences

All rights reserved.